Hikma Acquires Stake in Indian API Firm

10:52 PM MDT | April 18, 2011 | Deepti Ramesh

Hikma Pharmaceuticals (London) says it has agreed to acquire a minority interest in privately held Unimark Remedies (Mumbai), a manufacturer of active pharmaceutical ingredients (API) and pharma intermediates, for $33.3 million. The transaction is expected to be completed next month. Unimark’s product range includes betalactams, cephalosporins, carbapenems and covers several therapeutic segments including cardiovascular, anti-asthma and anti-infectives. Unimark operates three API facilities, two of which are approved by the U.S. FDA, and two R&D...